Publication

Title: In-house human immunodeficiency virus-1 genotype resistance testing to determine highly active antiretroviral therapy resistance mutations in Hong Kong
Authors: Chen JH, Wong KH, Li PC, Chan KK, Lee MP, To SW, Yam WC .
Journal: Hong Kong Med J,18:20-24 (2012)

Tweet

Abstract

This study evaluates the effectiveness of an in-house HIV-1 genotypic resistance test for detecting drug resistance mutations in patients undergoing highly active antiretroviral therapy (HAART) in Hong Kong. A total of 1165 plasma samples from 965 patients were analyzed, and the results were compared to the FDA-approved ViroSeq HIV-1 genotyping system. The in-house test demonstrated comparable performance at a significantly lower cost (US$40 per sample vs. US$160 for ViroSeq). Drug resistance mutations were only observed in post-treatment samples from patients with treatment failure. No significant differences in resistance mutation frequencies were found between HIV-1 subtype B and CRF01_AE, the predominant genotypes in Hong Kong. The findings suggest that cost-effective, in-house genotypic resistance testing could improve HIV treatment monitoring and drug resistance surveillance, particularly in resource-limited settings.

Download: Full text paper

Citation: Chen JH, Wong KH, Li PC, Chan KK, Lee MP, To SW, Yam WC . In-house human immunodeficiency virus-1 genotype resistance testing to determine highly active antiretroviral therapy resistance mutations in Hong Kong Hong Kong Med J,18:20-24 (2012).